Related Experiment Video
Updated: May 11, 2026
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Inhibition of microglial Slc2a5 attenuates ischemic brain injury
Daosheng Ai1, Baoshan Qiu2, Xing-Jun Chen1
1Academy for Advanced Interdisciplinary Studies (AAIS), Peking University, Beijing 100871, China; Chinese Institute for Brain Research, Beijing, Beijing 102206, China.
Abstract:
Acute ischemic stroke (AIS) is one of the leading causes of mortality and disability globally. Despite its complex pathological mechanisms, effective neuroprotective strategies are still lacking in clinical practice. Microglia and their metabolic processes play a pivotal role in the pathogenesis of AIS, yet the impact and underlying mechanisms of microglial fructose metabolism remain unclear. In this study, we identified Slc2a5 (also known as Glut5), a crucial regulator of fructose metabolism in microglia, as a key factor contributing to the early progression of AIS. Conditional deletion of Slc2a5 in microglia significantly alleviated brain injury in a mouse model of AIS. Single-cell transcriptomic (scRNA-seq) analysis demonstrated that the deletion of Slc2a5 promoted the differentiation of microglia into stroke-associated subpopulations with neuroprotective properties. Moreover, in vitro experiments indicated that this microglial differentiation process was primarily mediated by the activity of pyruvate kinase M2 (PKM2). Collectively, our findings unveil a novel microglial Slc2a5-mediated fructose metabolism pathway that exacerbates brain injury after AIS. This study provides evidence for SLC2A5 as a promising therapeutic target for the clinical treatment of AIS by offering insights into its critical role in microglial metabolism and neuroprotection.
Insights
Researchers discovered that blocking fructose metabolism in microglia, using Slc2a5 (Glut5), reduces brain damage after acute ischemic stroke (AIS). This Slc2a5 inhibition promotes neuroprotective microglial differentiation, offering a new therapeutic target for AIS.
Area of Science:
- Neuroscience
- Metabolic pathways
- Stroke research
Background:
- Acute ischemic stroke (AIS) is a major cause of death and disability worldwide.
- Effective neuroprotective treatments for AIS are limited.
- Microglial metabolism's role in AIS pathogenesis is not fully understood, particularly fructose metabolism.
Purpose of the Study:
- To investigate the role of microglial fructose metabolism in AIS.
- To identify key molecular regulators of this pathway.
- To explore potential therapeutic targets for AIS.
Main Methods:
- Identified Slc2a5 (Glut5) as a key regulator of microglial fructose metabolism in AIS.
- Utilized a mouse model of AIS with conditional deletion of Slc2a5 in microglia.
- Performed single-cell transcriptomic (scRNA-seq) analysis.
- Conducted in vitro experiments to study microglial differentiation and pyruvate kinase M2 (PKM2) activity.
Main Results:
- Conditional deletion of Slc2a5 in microglia significantly reduced brain injury in an AIS mouse model.
- Slc2a5 deletion promoted microglial differentiation into neuroprotective stroke-associated subpopulations.
- In vitro studies showed that pyruvate kinase M2 (PKM2) activity mediated this differentiation process.
Conclusions:
- A novel Slc2a5-mediated fructose metabolism pathway in microglia exacerbates brain injury post-AIS.
- Targeting Slc2a5 offers a promising therapeutic strategy for AIS.
- Understanding microglial metabolism is crucial for developing neuroprotective interventions.
